The global mRNA therapeutics market was valued at USD 8.91 billion in 2024 and is projected to be worth USD 6.01 billion in 2025, eventually reaching USD 21.45 billion by 2032. This represents a compound annual growth rate (CAGR) of 19.9% over the forecast period. In 2024, North America led the mRNA therapeutics market, accounting for a market share of 35.12%.

The mRNA therapeutics market is witnessing significant growth, primarily driven by the success of mRNA-based vaccines and expanding research into broader therapeutic applications. Prophylactic vaccines continue to dominate due to existing approvals and high global demand, while the drugs segment is rapidly advancing with a strong pipeline targeting cancer and genetic disorders. Infectious diseases remain the leading application area, though oncology is emerging as a major focus for future development. Distribution through hospital pharmacies remains dominant, supported by professional administration needs, while retail pharmacies are gaining momentum through enhanced accessibility and supportive health policies.

Continue reading for more details:

**https://www.fortunebusinessinsights.com/mrna-therapeutics-market-113411**

Market Segmentation

• By product type, the mRNA Therapeutics Market is segmented into prophylactic vaccines and therapeutic vaccines.
• By application, the market covers infectious diseases, oncology, rare genetic diseases, and other therapeutic areas.
• Based on delivery method, the mRNA Therapeutics Market includes lipid nanoparticles, cationic nanoemulsions, and polymer-based carriers.
• By end user, the market serves hospitals, specialty clinics, research laboratories, and contract manufacturing organizations.

List Of Key mRNA therapeutics Market Companies Profiled:

• Moderna Inc. (U.S.)
• BioNTech (Germany)
• Pfizer Inc. (U.S.)
• CureVac SE (Germany)
• GSK plc. (U.K.)
• Sanofi (France)
• Omega Therapeutics (U.S.)
• Strand Therapeutics (U.S.)
• Immunomic Therapeutics (U.S.)